Oral squamous cell carcinoma cells modulate osteoclast function by RANKL-dependent and -independent mechanisms

Cancer Letters

Volumn 274, Issue 1, 2009, Pages 126-131

  Tada, Takeyuki ^a   Shin, Masashi ^b   Fukushima, Hidefumi ^b   Okabe, Koji ^a   Ozeki, Satoru ^a   Okamoto, Masato ^c   Jimi, Eijiro ^b  

^a FUKUOKA DENTAL COLLEGE   (Japan)

^b KYUSHU DENTAL COLLEGE   (Japan)

^c MUSASHINO UNIVERSITY   (Japan)

Author keywords

Bone invasion; Oral squamous cell carcinoma; Osteoclasts; RANKL

Indexed keywords

BIM PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOMA CELL; CELL FUNCTION; CELL SURVIVAL; HOST CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOUSE; MOUTH CARCINOMA; MULTINUCLEAR CELL; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

APOPTOSIS REGULATORY PROTEINS; CARCINOMA, SQUAMOUS CELL; CELL SURVIVAL; HUMANS; IMMUNOBLOTTING; MEMBRANE PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MOUTH NEOPLASMS; OSTEOCLASTS; OSTEOPROTEGERIN; PROTO-ONCOGENE PROTEINS; RANK LIGAND; TUMOR CELLS, CULTURED;

EID: 57749121473     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.09.015     Document Type: Article

References (41)

1. Jordan R.C., and Daley T. Oral squamous cell carcinoma: new insights. J. Can. Dent. Assoc. 63 (1997) 521-525
2. Hicks Jr W.L., Loree T.R., Garcia R.I., Maamoun S., Marshall D., Orner J.B., Bakamjian V.Y., and Shedd D.P. Squamous cell carcinoma of the floor of mouth: a 20-year review. Head Neck 19 (1997) 400-405
3. Guise T.A., and Mundy G.R. Cancer and bone. Endocr. Rev. 19 (1998) 18-54
4. Baron R., Neff L., Louvard D., and Courtoy P.J. Cell-mediated extracellular acidification and bone resorption: evidence for a low pH in resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border. J. Cell Biol. 101 (1985) 2210-2222
5. Suda T., Takahashi N., Udagawa N., Jimi E., Gillespie M.T., and Martin T.J. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 203 (1999) 345-357
6. Nakashima T., Wada T., and Penninger J.M. RANKL and RANK as novel therapeutic targets for arthritis. Curr. Opin. Rheumatol. 15 (2003) 280-287
7. Boyle W.J., Simonet W.S., and Lacey D.L. Osteoclast differentiation and activation. Nature 423 (2003) 337-342
8. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., Tomoyasu A., Yano K., Goto M., Murakami A., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95 (1998) 3597-3602
9. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
10. Tsuda E., Goto M., Mochizuki S., Yano K., Kobayashi F., Morinaga T., and Higashio K. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun. 234 (1997) 137-142
11. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
12. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., Scully S., Tan H.L., Xu W., Lacey D.L., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12 (1998) 1260-1268
13. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., Morony S., Oliveira-dos-Santos A.J., Van G., Itie A., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397 (1999) 315-323
14. Jimi E., Akiyama S., Tsurukai T., Okahashi N., Kobayashi K., Udagawa N., Nishihara T., Takahashi N., and Suda T. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J. Immunol. 163 (1999) 434-442
15. Fuller K., Owens J.M., Jagger C.J., Wilson A., Moss R., and Chambers T.J. Macrophage colony-stimulating factor stimulates survival and chemotactic behavior in isolated osteoclasts. J. Exp. Med. 178 (1993) 1733-1744
16. Jimi E., Shuto T., and Koga T. Macrophage colony-stimulating factor and interleukin-1α maintain the survival of osteoclast-like cells. Endocrinology 136 (1995) 808-811
17. Jimi E., Nakamura I., Ikebe T., Akiyama S., Takahashi N., and Suda T. Activation of NF-κB is involved in the survival of osteoclasts promoted by interleukin-1. J. Biol. Chem. 273 (1998) 8799-8805
18. Selander K.S., Härkönen P.L., Valve E., Mönkkönen J., Hannuniemi R., and Väänänen H.K. Calcitonin promotes osteoclast survival in vitro. Mol. Cell. Endocrinol. 122 (1996) 119-129
19. Hughes D.E., Dai A., Tiffee J.C., Li H.H., Mundy G.R., and Boyce B.F. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β. Nat. Med. 2 (1996) 1132-1136
20. Kameda T., Mano H., Yuasa T., Mori Y., Miyazawa K., Shiokawa M., Nakamaru Y., Hiroi E., Hiura K., Kameda A., Yang N.N., Hakeda Y., and Kumegawa M. Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J. Exp. Med. 186 (1997) 489-495
21. Bendre M., Gaddy D., Nicholas R.W., and Suva L.J. Breast cancer metastasis to bone: it is not all about PTHrP. Clin. Orthop. 415 (2003) S39-45
22. Thomas R.J., Guise T.A., Yin J.J., Elliott J., Horwood N.J., Martin T.J., and Gillespie M.T. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140 (1999) 4451-4458
23. Lin D.L., Tarnowski C.P., Zhang J., Dai J., Rohn E., Patel A.H., Morris M.D., and Keller E.T. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 47 (2001) 212-221
24. Brown J.M., Corey E., Lee Z.D., True L.D., Yun T.J., Tondravi M., and Vessella R.L. Osteoprotegerin and rank ligand expression in prostate cancer. Urology 57 (2001) 611-616
25. Sezer O., Heider U., Zavrski I., Kuhne C.A., and Hofbauer L.C. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 101 (2003) 2094-2098
26. Yaccoby S., Wezeman M.J., Henderson A., Cottler-Fox M., Yi Q., Barlogie B., and Epstein J. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res. 64 (2004) 2016-2023
27. Nagai M., Kyakumoto S., and Sato N. Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation. Biochem. Biophys. Res. Commun. 269 (2000) 532-536
28. Farrugia A.N., Atkins G.J., To L.B., Pan B., Horvath N., Kostakis P., Findlay D.M., Bardy P., and Zannettino A.C. Receptor activator of nuclear factor-κB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res. 63 (2003) 5438-5445
29. Giuliani N., Bataille R., Mancini C., Lazzaretti M., and Barille S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98 (2001) 3527-3533
30. Ohshiba T., Miyaura C., and Inada M. Ito A. Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis. Br. J. Cancer 88 (2003) 1318-1326
31. Okamoto M., Hiura K., Ohe G., Ohba Y., Terai K., Oshikawa T., Furuichi S., Nishikawa H., Moriyama K., Yoshida H., and Sato M. Mechanism for bone invasion of oral cancer cells mediated by interleukin-6 in vitro and in vivo. Cancer 89 (2000) 1966-1975
32. Tada T., Jimi E., Okamoto M., Ozeki S., and Okabe K. Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteobalsts. Int. J. Cancer 116 (2005) 253-262
33. Jimi E., Nakamura I., Duong L.T., Ikebe T., Takahashi N., Rodan G.A., and Suda T. Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp. Cell Res. 247 (1999) 84-93
34. Jimi E., Nakamura I., Amano H., Taguchi Y., Tsurukai T., Tamura M., Takahashi N., and Suda T. Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact. Endocrinology 137 (1996) 2187-2190
35. Miyazaki T., Katagiri H., Kanegae Y., Takayanagi H., Sawada Y., Yamamoto A., Pando M.P., Asano T., Verma I.M., Oda H., Nakamura K., and Tanaka S. Reciprocal role of ERK and NF-κB pathways in survival and activation of osteoclasts. J. Cell Biol. 148 (2000) 333-342
36. Lee S.E., Chung W.J., Kwak H.B., Chung C.H., Kwack K.B., Lee Z.H., and Kim H.H. Tumor necrosis factor-α supports the survival of osteoclasts through the activation of Akt and ERK. J. Biol. Chem. 276 (2001) 49343-49349
37. Akiyama T., Bouillet P., Miyazaki T., Kadono Y., Chikuda H., Chung U.I., Fukuda A., Hikita A., Seto H., Okada T., et al. Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3-only Bcl-2 family member Bim. EMBO J. 22 (2003) 6653-6664
38. Kukita T., Wada N., Kukita A., Kakimoto T., Sandra F., Toh K., Nagata K K., Iijima T., Horiuchi M., Matsusaki H., et al. RANKL-induced DC-STAMP is essential for osteoclastogenesis. J. Exp. Med. 200 (2004) 941-946
39. Yagi M., Miyamoto T., Sawatani Y., Iwamoto K., Hosogane N., Fujita N., Morita K., Ninomiya K., Suzuki T., Miyamoto K., et al. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J. Exp. Med. 202 (2005) 345-351
40. Yagi M., Ninomiya K., Fujita N., Suzuki T., Iwasaki R., Morita K., Hosogane N., Matsuo K., Toyama Y., Suda T., and Miyamoto T. Induction of DC-STAMP by alternative activation and downstream signaling mechanisms. J. Bone Miner. Res. 22 (2007) 992-1001
41. Kobayashi K., Takahashi N., Jimi E., Udagawa N., Takami M., Kotake S., Nakagawa N., Kinosaki M., Yamaguchi K., Shima N., et al. Tumor necrosis factor a stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med. 191 (2000) 275-286